Aldeyra Therapeutics Inc. has released a presentation detailing its innovative pharmaceutical developments for immune-mediated and metabolic diseases. The company highlights its approach to modulating protein systems to optimize multiple pathways while minimizing toxicity. The presentation outlines Aldeyra's well-capitalized status and its extensive pipeline, which includes the development of Reproxalap for dry eye disease and allergic conjunctivitis, as well as other treatments for conditions such as atopic dermatitis and moderate alcohol-associated hepatitis. As of May 14, 2025, Aldeyra reported having $90.1 million in cash, cash equivalents, and marketable securities, projected to fund operations into 2027. You can access the full presentation through the link below.